biotech-investing
(5)
Dylan Jovine Learned the Market's Cruelest Lesson at $2.43 a Share
Before Dylan Jovine built research firms for individual investors, one Thanksgiving trade erased 90% of his savings. The mistake still explains how he reads companies, risk and the seduction of certainty.
Behind the Markets Sells Retail Investors the Stocks Wall Street Skips - But the Real Product Is Conviction
Dylan Jovine built a Florida research shop around a sharp observation: big funds ignore thousands of smaller companies. The opportunity is real, the subscriptions can cost thousands, and the uncomfortable part is knowing when conviction has become marketing.
The Biotech Fund That Likes the Awkward Middle
Agent Capital invests where molecules, milestones and money collide. Its small team backs healthcare companies across the development curve, then stays close enough to help science become a financeable business.
The Statehouse That Learned to Pick Winners
For 35 years, Connecticut has run a venture fund out of the statehouse. In fiscal 2026 it returned a record $66.5 million - proof that a government can, occasionally, invest like a Sand Hill Road firm.
The Fund That Put a Border Around Its Ambition
Most investors diversify by geography. The O.H.I.O. Fund does the opposite - using an Ohio-only mandate, a multi-asset portfolio and a local network to turn home-state knowledge into an investing edge.